Difference between revisions of "Part:BBa K404114"
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K404114 short</partinfo> | <partinfo>BBa_K404114 short</partinfo> | ||
+ | <br /> | ||
+ | {| style="color:black" cellpadding="6" cellspacing="1" border="2" align="right" | ||
+ | ! colspan="2" style="background:#66bbff;"|[https://parts.igem.org/Part:BBa_K404114 [AAV2]-left-ITR_pCMV] | ||
+ | |- | ||
+ | ! colspan="2"|[[Image:Freiburg10_Vectorplasmid precursors 1.png|200px]] | ||
+ | |- | ||
+ | |'''BioBrick Nr.''' | ||
+ | |[https://parts.igem.org/Part:BBa_K404114 BBa_K404114] | ||
+ | |- | ||
+ | |'''RFC standard''' | ||
+ | |[https://parts.igem.org/Help:Assembly_standard_10 RFC 10] | ||
+ | |- | ||
+ | |'''Requirement''' | ||
+ | |pSB1C3<br> | ||
+ | |- | ||
+ | |'''Source''' | ||
+ | |pAAV_MCS provided by Stratagene | ||
+ | |- | ||
+ | |'''Submitted by''' | ||
+ | |[http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] | ||
+ | |} | ||
+ | <br /> | ||
− | [[Image:Freiburg10_Vectorplasmid precursors 1.png| | + | [[Image:Freiburg10_Vectorplasmid precursors 1.png|left|thumb|480px]]<br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /> |
<html> | <html> | ||
<head> | <head> | ||
Line 75: | Line 97: | ||
<body lang="EN-US"> | <body lang="EN-US"> | ||
<div class="WordSection1"> | <div class="WordSection1"> | ||
− | <p class="MsoNormal"><span class="apple-style-span"><b><span | + | <p class="MsoNormal"><span class="apple-style-span"><b><u><span |
− | style="font-size: 14.5pt; line-height: 115%; font-family: "Arial","sans-serif";"></span></b></span>< | + | style="font-size: 14.5pt; line-height: 115%; font-family: "Arial","sans-serif";">[AAV2]-left-ITR_pCMV</span></u></b></span></p> |
− | <span style="font-size: 10pt; line-height: 115%;">Producing | + | <p class="MsoNormal" style="text-align: justify;"><span |
− | recombinant virus particles for therapeutical applications is, besides | + | style="font-size: 10pt; line-height: 115%;">Producing |
− | specific | + | recombinant virus particles for therapeutical applications |
− | cell targeting, purification and quantification assays of AAV-2, one | + | is, besides specific cell targeting, purification and quantification |
− | intention | + | assays of |
− | of the Virus Construction Kit provided by the iGEM team | + | AAV-2, one intention of the Virus Construction Kit provided by the iGEM |
− | Freiburg_Bioware 2010. | + | team |
− | For obtaining a modular toolkit, the complex biological system of the | + | Freiburg_Bioware 2010. For obtaining a modular toolkit, the complex |
− | Adeno-associated virus serotype 2 was examined by an exhaustive | + | biological |
− | literature | + | system of the Adeno-associated virus serotype 2 was examined by an |
− | search. Subsequently, the essential components for AAV-2 particle | + | exhaustive |
− | production | + | literature search. Subsequently, the essential components for AAV-2 |
− | were extracted and redesigned to match the iGEM standard.</span></p> | + | particle |
− | <p class="MsoNormal"><span | + | production were extracted and redesigned to match the iGEM standard.</span></p> |
+ | <p class="MsoNormal" style="text-align: justify;"><span | ||
style="font-size: 10pt; line-height: 115%;">The provided | style="font-size: 10pt; line-height: 115%;">The provided | ||
− | tripartite system is independent of a superinfection of | + | tripartite system is independent of a |
− | Adeno- or herpes | + | superinfection of Adeno- or herpes simplex viruses since the |
− | simplex viruses since the genes encoding the required helper-proteins | + | genes encoding |
− | are | + | the required helper-proteins are co-transfected. Inside the eukaryotic |
− | co-transfected. Inside the eukaryotic host cell, the DNA sequence | + | host |
− | containing | + | cell, the DNA sequence containing the inverted terminal repeats (ITRs) |
− | the inverted terminal repeats (ITRs) is extracted and later | + | is extracted |
− | encapsidated into | + | and later encapsidated into the preformed capsids after production of |
− | the preformed capsids after production of single-stranded DNA. | + | single-stranded DNA. Consequently, this plasmid is known as the vector |
− | Consequently, | + | plasmid |
− | this plasmid is known as the vector plasmid (pGOI). Promoter, <i>beta-globin</i> | + | (pGOI). Promoter, <i>beta-globin</i> intron and the hGH |
− | intron and the hGH terminator signal are flanked by the ITRs (ITRs, | + | terminator signal are |
− | BBa_K404100 | + | flanked by the ITRs (ITRs, BBa_K404100 and BBa_K404101) and regulate |
− | and BBa_K404101) and regulate transgene expression. The vector plasmid | + | transgene |
− | containing the desired gene of interest is cotransfected with the | + | expression. The vector plasmid containing the desired gene of interest |
− | RepCap | + | is |
− | plasmid (BBa_K404001, BBa_K404002 or BBa_K404003) and the pHelper | + | cotransfected with the RepCap plasmid (BBa_K404001, BBa_K404002 or |
− | plasmid. To | + | BBa_K404003) |
− | obtain the fully assembled vector plasmid, several assembly steps have | + | and the pHelper plasmid. To obtain the fully assembled vector plasmid, |
− | to be | + | several |
− | performed. </span></p> | + | assembly steps have to be performed. </span></p> |
− | <p class="MsoNormal"><span | + | <p class="MsoNormal" style="text-align: justify;"><span |
− | style="font-size: 10pt; line-height: 115%;">Facilitating | + | style="font-size: 10pt; line-height: 115%;">Facilitating the |
− | the cloning steps, the iGEM team Freiburg_Bioware 2010 provides the | + | cloning steps, the iGEM team |
− | 5´nucleotide components in respect to the desired gene of interest, | + | Freiburg_Bioware 2010 provides the 5´nucleotide components in respect |
− | consisting | + | to the |
− | of the left inverted terminal repeat (</span><span | + | desired gene of interest, consisting of the left inverted terminal |
+ | repeat (</span><span | ||
style="font-size: 10pt; line-height: 115%;">BBa_K404100</span><span | style="font-size: 10pt; line-height: 115%;">BBa_K404100</span><span | ||
style="font-size: 10pt; line-height: 115%;">) followed by | style="font-size: 10pt; line-height: 115%;">) followed by | ||
Line 127: | Line 151: | ||
</body> | </body> | ||
</html> | </html> | ||
+ | |||
+ | |||
+ | |||
+ | |||
Latest revision as of 15:48, 27 October 2010
[AAV2]-left-ITR_pCMV
[AAV2-left-ITR_pCMV] | |
---|---|
BioBrick Nr. | BBa_K404114 |
RFC standard | RFC 10 |
Requirement | pSB1C3 |
Source | pAAV_MCS provided by Stratagene |
Submitted by | [http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] |
[AAV2]-left-ITR_pCMV
Producing recombinant virus particles for therapeutical applications is, besides specific cell targeting, purification and quantification assays of AAV-2, one intention of the Virus Construction Kit provided by the iGEM team Freiburg_Bioware 2010. For obtaining a modular toolkit, the complex biological system of the Adeno-associated virus serotype 2 was examined by an exhaustive literature search. Subsequently, the essential components for AAV-2 particle production were extracted and redesigned to match the iGEM standard.
The provided tripartite system is independent of a superinfection of Adeno- or herpes simplex viruses since the genes encoding the required helper-proteins are co-transfected. Inside the eukaryotic host cell, the DNA sequence containing the inverted terminal repeats (ITRs) is extracted and later encapsidated into the preformed capsids after production of single-stranded DNA. Consequently, this plasmid is known as the vector plasmid (pGOI). Promoter, beta-globin intron and the hGH terminator signal are flanked by the ITRs (ITRs, BBa_K404100 and BBa_K404101) and regulate transgene expression. The vector plasmid containing the desired gene of interest is cotransfected with the RepCap plasmid (BBa_K404001, BBa_K404002 or BBa_K404003) and the pHelper plasmid. To obtain the fully assembled vector plasmid, several assembly steps have to be performed.
Facilitating the cloning steps, the iGEM team Freiburg_Bioware 2010 provides the 5´nucleotide components in respect to the desired gene of interest, consisting of the left inverted terminal repeat (BBa_K404100) followed by the CMV promoter (BBa_K404102).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]